Skip to content

Effect of intercostal nerve injection of liposomal bupivacaine versus ropivacaine on pulmonary atelectasis after thoracoscopic lobectomy: a single center, randomized, double-blind, clinical study

Effect of intercostal nerve injection of liposomal bupivacaine versus ropivacaine on pulmonary atelectasis after thoracoscopic lobectomy

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300077516
Enrollment
Unknown
Registered
2023-11-10
Start date
2024-07-08
Completion date
Unknown
Last updated
2025-07-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atelectasis is one of the most common respiratory complications after surgery, specifically complete or partial atrophy of the whole or part of the lung (lobe). It is commonly seen when the tiny air sacs (alveoli) in the lungs atrophy or fill with alveolar fluid, among other things

Interventions

Experimental group:Intercostal nerve block was performed at the surgical incision site and its two adjacent segments (one above and one below the incision) using liposomal bupivacaine. The total dose
Control group:Intercostal nerve block was performed at the surgical incision site and its two adjacent segments (one above and one below the incision) using ropivacaine. The ropivacaine injection was

Sponsors

The Affiliated Hospital of Southwest Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Patients who are aware of and agree to participate in this clinical observation; 2. Aged 18-60 years; 3. No tumor metastatic lesions were found before the operation, and they had not received related surgery and chemotherapy; 4. No obvious cardiopulmonary function abnormality, normal liver and kidney function before surgery.

Exclusion criteria

Exclusion criteria: 1. Emergency surgery; 2. Preoperative cardiac function grading greater than or equal to grade III, or combined severe cardiac, cerebrovascular diseases, peptic ulcer and bleeding, liver and kidney function damage, neuro-psychiatric system diseases, dementia, psychological diseases, etc; 3. Preoperative combination of moderate or severe chronic obstructive pulmonary disease, pulmonary pustules, severe bronchial dilatation, silicosis, pleural effusion, pyothorax, pleural or chest wall diseases; 4. Patients with contraindications to nerve block (severe coagulation disorders, systemic or localized infections; 5. Patients with difficult airway and difficult intubation; 6. The patient refuses to participate or the investigator believes that the patient is not a good candidate for the clinical trial.

Design outcomes

Primary

MeasureTime frame
Dependent silent space (DSS) and Global inhomogeneity (GI);

Secondary

MeasureTime frame
Lung aeration compartments;Pain scores;

Countries

China

Contacts

Public ContactYingying Zhang

The Affiliated Hospital of Southwest Medical University

yingyingzhang917@gmail.com+86 189 8279 6195

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026